1700003E16Rik Inhibitors
Chemical inhibitors of the protein encoded by the gene 1700003E16Rik can exert their inhibitory effects through various mechanisms impacting the protein's activity. Wortmannin and LY294002 specifically target phosphoinositide 3-kinases, which are essential for the activation of the AKT signaling pathway. The protein encoded by 1700003E16Rik is a downstream effector in this pathway, and its functional activity is contingent upon phosphorylation events mediated by PI3K. By inhibiting PI3K, these compounds prevent the activation of AKT, leading to a decrease in the phosphorylation and activation of the 1700003E16Rik protein. Rapamycin, another inhibitor, acts by binding to FKBP12 and specifically inhibiting the mTOR complex 1, a crucial component in the PI3K/AKT/mTOR pathway. This inhibition disrupts the pathway at a point downstream of AKT, which in turn impacts the activity of the 1700003E16Rik protein.
Continuing with the theme of inhibiting key signaling pathways, Triciribine directly targets AKT, preventing its phosphorylation and subsequent activation. The activity of the 1700003E16Rik protein is dependent on these phosphorylation events, which are halted by Triciribine. U0126 and PD98059 exert their inhibitory effects on the mitogen-activated protein kinase (MAPK/ERK) pathway. They specifically inhibit MEK1/2, which are upstream of ERK, preventing the activation of this kinase cascade that may regulate the 1700003E16Rik protein. In a similar vein, SP600125 and SB203580 are inhibitors of the JNK and p38 MAP kinase pathways, respectively. By inhibiting these kinases, they interfere with the stress and cytokine response signaling pathways, which can regulate the activity of proteins like the one encoded by 1700003E16Rik. Erlotinib and Gefitinib inhibit the epidermal growth factor receptor tyrosine kinase, thereby disrupting downstream signaling that could affect the activity of the 1700003E16Rik protein. Staurosporine, being a broad-spectrum protein kinase inhibitor, impacts multiple kinases within the signaling pathways, potentially leading to the inhibition of the 1700003E16Rik protein. Lastly, Sorafenib targets various tyrosine protein kinases and RAF kinases within the MAPK pathway, which ultimately can disrupt the signaling cascade affecting the protein activity encoded by 1700003E16Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits phosphoinositide 3-kinases (PI3Ks), which are upstream regulators of the AKT signaling pathway. Since 1700003E16Rik is involved in PI3K/AKT signaling, inhibition of PI3K by Wortmannin would prevent AKT activation, thereby functionally inhibiting 1700003E16Rik by preventing its phosphorylation and subsequent activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3Ks, LY294002 directly blocks the ATP binding site of these kinases. As with Wortmannin, by blocking PI3K activity, LY294002 would inhibit the activation of AKT and downstream signaling components, including 1700003E16Rik, leading to a functional inhibition of its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to FKBP12 and inhibits the mTOR complex 1 (mTORC1), a key downstream effector in the PI3K/AKT/mTOR pathway. By inhibiting mTORC1, Rapamycin disrupts the pathway that 1700003E16Rik is part of, leading to functional inhibition of 1700003E16Rik due to the suppression of necessary signaling events for its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Specifically inhibits the phosphorylation and activation of AKT. Triciribine's inhibition of AKT would lead to a functional inhibition of 1700003E16Rik by blocking the signaling necessary for its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK, which is upstream of the ERK pathway. By blocking MEK, U0126 inhibits ERK phosphorylation and activation. As the ERK pathway can regulate proteins involved in the same processes as 1700003E16Rik, inhibiting ERK signaling could lead to a functional inhibition of 1700003E16Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that prevents the activation of MAPK/ERK, thereby inhibiting downstream signaling events. PD98059 would functionally inhibit 1700003E16Rik by blocking the signaling pathways that regulate its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress- and cytokine-induced signaling pathways. By inhibiting JNK, SP600125 could functionally inhibit 1700003E16Rik through disruption of JNK-mediated signaling pathways that are necessary for the full functional activity of 1700003E16Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Specifically inhibits p38 MAP kinase, which is involved in response to stress and inflammatory cytokines. SB203580 could lead to functional inhibition of 1700003E16Rik by blocking the p38 MAPK signaling pathways that regulate the activity of proteins within the same pathway as 1700003E16Rik. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
An inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting EGFR, Erlotinib disrupts the downstream signaling pathways, including those that may regulate or involve 1700003E16Rik, leading to its functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Similar to Erlotinib, Gefitinib is an EGFR tyrosine kinase inhibitor that would functionally inhibit 1700003E16Rik by disrupting EGFR-mediated signaling pathways that regulate or include 1700003E16Rik. | ||||||